Search

Displaying results 241 - 250 of 4265 in total
  1. Drug

    Afimoxifene

    go.drugbank.com/drugs/DB04468
    Investigational

    This technology enables percutaneous delivery of drugs that cannot be delivered orally. It is being developed by Ascent Therapeutics.

  2. Drug

    Solriamfetol

    go.drugbank.com/drugs/DB14754
    ApprovedInvestigational

    Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated

  3. Drug

    Etacrynic acid

    go.drugbank.com/drugs/DB00903
    ApprovedInvestigational

    A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules.

  4. Drug

    Floxuridine

    go.drugbank.com/drugs/DB00322
    ApprovedInvestigational

    When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. … An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution.

  5. Drug

    Citalopram

    go.drugbank.com/drugs/DB00215
    ApprovedInvestigational

    [A261316] Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.[L5230]

  6. Drug

    AI-850

    go.drugbank.com/drugs/DB05842
    Experimental

    AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.

  7. Drug

    Sovateltide

    go.drugbank.com/drugs/DB06138
    Investigational

    In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. It is being developed as an adjunct to chemotherapy.

  8. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker.

  9. Drug

    Netilmicin

    go.drugbank.com/drugs/DB00955
    Approved

    Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. … Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site.

  10. Drug

    Tobramycin

    go.drugbank.com/drugs/DB00684
    ApprovedInvestigational

    [A232294, A232349, L32739, L32749] Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to … [A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.